1. EMA Summary of Product Characteristics - Praxbind, INN-Idarucizumab. cited 2022 December 05; Available from: https://www.ema.europa.eu/en/documents/product-information/praxbind-epar-product-information_en.pdf.
2. FDA Product Information - PRAXBIND (idarucizumab). cited 2022 December 05; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf.
3. Idarucizumab for dabigatran reversal - full cohort analysis;Pollack;N. Engl. J. Med.,2017
4. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews;Page;Bmj,2021
5. Joanna Briggs Institute (JBI) Critical Appraisal Tool - Checklist for Case Series. cited 2022 December 01; Available from: https://jbi.global/critical-appraisal-tools.